Company Profiles

driven by the PitchBook Platform

Synchroneuron

Description

Developer of drug therapies designed to treat tardive dyskinesia and other neuropsychiatric disorders. The company's drug therapies simultaneously affects excitatory and inhibitory pathways, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

2011

Founded

PRIVATE

Status

1-10

Employees

Series B

Latest Deal Type

$20M

Latest Deal Amount

$26M

Total Amount Raised

Description

Developer of drug therapies designed to treat tardive dyskinesia and other neuropsychiatric disorders. The company's drug therapies simultaneously affects excitatory and inhibitory pathways, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Website:

www.synchroneuron.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Therapeutic Devices

Primary Office

130 Tobey Garden Street Duxbury, MA 02332United States +1 (617) 538-5688
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Synchroneuron's full profile, request a free trial.

    Synchroneuron Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Synchroneuron Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Synchroneuron Investors (1)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Morningside GroupVenture CapitalMinority000 0000000 0000
    Morningside Group Venture Capital

    Synchroneuron Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    William KernsInterim Chief Executive Officer, Board Member & Co-Founder
    Marc CoteChief Operating Officer, Chief Financial Officer & Co-Founder
    Kei-Lai Fong Ph.DExecutive Vice President, Development & Co-Founder
    William Kerns Interim Chief Executive Officer, Board Member & Co-Founder
    Marc Cote Chief Operating Officer, Chief Financial Officer & Co-Founder
    Kei-Lai Fong Ph.D Executive Vice President, Development & Co-Founder

    Synchroneuron Board Members (2)

    NameRepresentingRoleSinceContact
    Info
    Gerald Chan Ph.DMorningside GroupCo-Founder & Chairman000 0000
    Isaac Cheng MDMorningside GroupInvestor000 0000
    Gerald Chan Ph.D Co-Founder & Chairman Morningside Group
    Isaac Cheng MD Investor Morningside Group
    Request full access to PitchBook